MA63062A1 - Administration orale d'oligonucléotides - Google Patents
Administration orale d'oligonucléotidesInfo
- Publication number
- MA63062A1 MA63062A1 MA63062A MA63062A MA63062A1 MA 63062 A1 MA63062 A1 MA 63062A1 MA 63062 A MA63062 A MA 63062A MA 63062 A MA63062 A MA 63062A MA 63062 A1 MA63062 A1 MA 63062A1
- Authority
- MA
- Morocco
- Prior art keywords
- oligonucleotide
- present
- rna
- oral administration
- cnac
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 2
- XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 abstract 2
- 108091070501 miRNA Proteins 0.000 abstract 2
- 239000002679 microRNA Substances 0.000 abstract 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical class CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 108091023037 Aptamer Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091027967 Small hairpin RNA Proteins 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000004055 small Interfering RNA Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des compositions oligonucléotidiques comprenant (1) un oligonucléotide de la présente invention, par exemple, un aptamère d'aso, parni, petit arn en épingle à cheveux, adn ou arn, un vecteur de thérapie génique, un miarn, un mimétique de miarn, un anti-mir, un adn ou un leurre d'arn, un oligonucléotide cpg ou tout oligonucléotide thérapeutique ou de diagnostic connu de l'état de la technique, et (ii) un dérivé d'acide caprylique, par exemple 5-cnac. Dans certains aspects, la composition oligonucléotidique est formulée pour être administrée au tractus gastro-intestinal. Ainsi, certains aspects de la présente invention concernent des compositions oligonucléotidiques pour administration orale comprenant un oligonucléotide thérapeutique ou de diagnostic (par exemple, un aso) et un dérivé d'acide caprylique (par exemple, 5-cnac ou un de ses dérivés).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178361P | 2021-04-22 | 2021-04-22 | |
| PCT/US2022/025807 WO2022226217A1 (fr) | 2021-04-22 | 2022-04-21 | Administration orale d'oligonucléotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA63062A1 true MA63062A1 (fr) | 2024-03-29 |
Family
ID=91034141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA63062A MA63062A1 (fr) | 2021-04-22 | 2022-04-21 | Administration orale d'oligonucléotides |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA63062A1 (fr) |
-
2022
- 2022-04-21 MA MA63062A patent/MA63062A1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160074525A1 (en) | Novel single chemical entities and methods for delivery of oligonucleotides | |
| JP2018527013A5 (fr) | ||
| JP3926840B2 (ja) | 遺伝子発現をダウンレギュレートするための２’−置換オリゴヌクレオチドの使用 | |
| JP2021011505A (ja) | ペプチドオリゴヌクレオチドコンジュゲート | |
| US8691580B2 (en) | Single chemical entities and methods for delivery of oligonucleotides | |
| US20130137668A1 (en) | Antimicrobial Cationic Steroids and Methods of Use | |
| JP2016513976A5 (fr) | ||
| AU2015372560B2 (en) | Antisense antibacterial compounds and methods | |
| US10532068B2 (en) | Dual molecular delivery of oligonucleotides and peptide containing conjugates | |
| JP2022040131A5 (fr) | ||
| CO2023015745A2 (es) | Administración oral de oligonucleótidos | |
| Holder et al. | Neutrophil extracellular traps exert potential cytotoxic and proinflammatory effects in the dental pulp | |
| JP2018506272A5 (fr) | ||
| MA63062A1 (fr) | Administration orale d'oligonucléotides | |
| TWI740866B (zh) | 肽寡核苷酸結合物 | |
| JPWO2021187392A5 (fr) | ||
| US9492470B2 (en) | Use of HMGA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells | |
| JP2015203014A (ja) | 脊髄組織標的化ペプチド及びその利用 | |
| ES2895275T3 (es) | Enfoque novedoso para el tratamiento de trastornos inflamatorios | |
| AR125443A1 (es) | Administración oral de oligonucleotidos | |
| US20230165889A1 (en) | CHEMICALLY MODIFIED TRANSFER RNA-DERIVED SMALL RNAs (tsRNAs) TO TARGET PATHOGENIC BACTERIA | |
| Iskander | Insights into the Immune Response to Viral Infection of “COVID-19” | |
| Stambouli et al. | CA4-Pustulose exanthématique aiguë localisée à la moutarde des champs (Sinapis arvensis) | |
| JPWO2021239825A5 (fr) | ||
| FR2834465A1 (fr) | Compositions pour la vectorisation d'oligonucleotides a travers la barriere hematoencephalique et leur utilisation pour le traitement des maladies du systeme nerveux central |